IPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK?
|
|
- Jonathan Brooks
- 6 years ago
- Views:
Transcription
1 IPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK? KEVIN K. BROWN, MD PROFESSOR AND VICE CHAIRMAN, DEPARTMENT OF MEDICINE NATIONAL JEWISH HEALTH DENVER, CO Kevin K. Brown, MD, is a Professor and Vice Chairman in the Department of Medicine at National Jewish Health. He has had a long-standing interest in the clinical and biologic aspects of fibrosing lung disease and has directed National Jewish s Interstitial Lung Disease Program for two decades. Dr. Brown has leadership positions in a number of national and international pulmonary organizations, and serves on the steering and protocol development committees of multiple national and international multi-centered treatment trials in lung fibrosis. Named as one of the nation s top physicians for more than a decade, he has an active clinical practice as well as an NIH-funded translational research program focused on the development, progression, and control of fibrosing lung diseases. OBJECTIVES: Participants should be better able to: 1. To classify and distinguish among causes of pulmonary fibrosis; 2. To diagnose Idiopathic Pulmonary Fibrosis (IPF); 3. To assess the newly available treatments for IPF. FRIDAY, MARCH 13, :30 AM 1
2 IPF and other Fibrosing Lung Diseases: What Drugs Might Work and On Whom Do They Work? Kevin K. Brown, MD Professor and Vice Chair Department of Medicine National Jewish Health Denver, CO NAMDRC 2015 March 15, 2015 Scottsdale, AZ DISCLOSURE Dr. Brown has received research grants from NHLBI, Actelion, Amgen, Gilead and participates in consulting and speakers bureau activities for Actelion, Almiral, Altitude Pharma, Amgen, Astra Zeneca, Bayer, Biogen/Stromedix, Boehringer Ingelheim, Celgene, Centocor, Fibrogen, Galecto, Gilead, GlaxoSmith Kline, Medmmune, Novartis, Pfizer, Promedior, Roche/Genentech, Sanofi/Genzyme, Veracyte, but these do not create a conflict related to the following presentation. 2
3 The problem 3
4 4
5 The interstitial lung diseases include a wide variety of pulmonary disorders that diffusely affect all anatomic compartments of the lung. 5
6 The interstitial lung diseases include a wide variety of pulmonary disorders that diffusely affect all anatomic compartments of the lung. The final diagnosis often requires information from a number specialties Chest imaging pattern Clinical context Pathologic pattern 6
7 Chest imaging pattern Clinical context Pathologic pattern Diagnosis 7
8 Significant pulmonary fibrosis occurs in which of the following clinical contexts? 1. Drug-induced Lung Disease 2. Hypersensitivity Pneumonitis 3. Uncharacterized Connective Tissue Disease 4. All of the above Significant pulmonary fibrosis occurs in which of the following clinical contexts? 1. Drug-induced Lung Disease 2. Hypersensitivity Pneumonitis 3. Uncharacterized Connective Tissue Disease 4. All of the above 0% 0% 0% 0%
9 Clinical context Chest imaging pattern Pathologic pattern Interstitial Lung Disease Infection Systemic Disorders Idiopathic disorders Exposures Genetic Conditions 9
10 Interstitial Lung Disease Atypical Pneumonia Infection Mycoplasma Chlamydia Viral Pneumocystis Mycobacterial Interstitital Lung Disease Infection Familial Interstitial Pneumonia Hermansky Pudlak Genetic Conditions 10
11 Infection Interstitial Lung Disease Systemic Disorders Sarcoidosis Connective Tissue Disease Immunodeficiency Malignancy Genetic Conditions Survival is shortened in RA Solomon et al, submitted 11
12 ExRA shortens survival in RA Solomon et al, submitted ILD shortens survival in RA Solomon et al, submitted 12
13 ILD shortens survival in RA Solomon et al, submitted Pulmonary Fibrosis shortens survival in RA Solomon JJ et al, Resp Med
14 Infection Interstitial Lung Disease Medications/Drugs/Tobacco Systemic Disorders Occupational Avocational Environmental Accidental Exposures Genetic Conditions Fibrosis predicts mortality in HP median survival > 20 yrs median survival 7.1 yrs p = Vourlekis et al, Am J Med
15 Interstitial Lung Disease Alveolar Proteinosis (PAP) Infection Lymphangioleiomyomatosis (LAM) Systemic Disorders Pulmonary Langerhans Cell Histiocytosis (PLCH) Exposures Idiopathic disorders Genetic Conditions Idiopathic interstitial pneumonias (IIP) Idiopathic Pulmonary Fibrosis (IPF) Nonspecific Interstitial Pneumonia (NSIP) Cryptogenic Organizing Pneumonia (COP) Desquamative Interstitial Pneumonia/ Respiratory Bronchiolitis-ILD (DIP/RBILD) Acute Interstitial Pneumonia (AIP) 15
16 Raghu et al, Am J Respir Crit Care Med : In most patients, which of the following is not required for a definitive diagnosis of IPF? 1. High-resolution CT scan of the chest 2. Surgical Lung Biopsy 3. Exclusion of competing causes of pulmonary fibrosis 4. All of the above are required 16
17 In most patients, which of the following is not required for a definitive diagnosis of IPF? 1. High-resolution CT scan of the chest 2. Surgical Lung Biopsy 3. Exclusion of competing causes of pulmonary fibrosis 4. All of the above are required 0% 0% 0% 0% In 2015 the diagnosis of IPF requires: 1. Exclusion of other known causes of interstitial lung disease (e.g., domestic exposures, connective tissue disease, and drug toxicity). 2. The presence of a UIP chest imaging pattern on HRCT in patients not subjected to surgical lung biopsy. 3. Specific combinations of HRCT chest imaging patterns and pathologic patterns in patients who undergo a surgical lung biopsy. 17
18 Is this IPF? Identifiable cause/association? No Yes UIP pattern HRCT pattern Not UIP Surgical lung biopsy Not UIP UIP pattern IPF Not IPF The problem with IPF 18
19 Survival in IPF is short Median survival years King et al, Am J Respir Crit Care Med 2000 Quality of life with IPF is poor Martinez TY et al, Chest
20 Functional Status in IPF is impaired Olson A et al, submitted Hospital admissions have increased 5%/year Navaratnam V et al, Chest
21 Which of the following is the most frequent cause of death in IPF patients? 1. Acute exacerbation of disease 2. Gradual disease progression with respiratory failure 3. Pneumonia 4. Ischemic heart disease Which of the following is the most frequent cause of death in IPF patients? 1. Acute exacerbation of disease 2. Gradual disease progression with respiratory failure 3. Pneumonia 4. Ischemic heart disease 1. 0% 0% 0% 0%
22 IPF patients die from their disease Olson et al, Am J Respir Crit Care Med 2007 Specific causes of death King, et al Lancet
23 Specific causes of death King, et al Lancet 2009 Specific causes of death Daniels, et al Eur Respir J 2008; 32:
24 Mortality Rate per 1,000,000 Mortality Rate per 1,000,000 Mortality Rates with Lung Cancer Age-Adjusted Mortality Rates With Lung Cancer per 1,000, Men - Lung Cancer Women - Lung Cancer The age-adjusted mortality rates with lung cancer: In men decreased by 21% In women increased by 7% Year Mortality Rates with COPD 1992 through 2003 Age-Adjusted Mortality Rates for Decedents with COPD per 1,000, through Men - COPD Women - COPD The age-adjusted mortality rates with COPD: In men decreased by 7% In women increased by 27% Year 24
25 From , rates have increased by 55% From 1992 to 2003, the age-adjusted mortality rates increased. In men increased by 28% from 48 per 1,000,000 to 62 per 1,000,000 In women increased by 40% from 40 per 1,000,000 to 56 per 1,000,000 Olson et al, Am J Respir Crit Care Med 2007 The clinical course is unpredictable 25
26 Untreated IPF progresses Carrington CB. NEJM, 1978 Untreated IPF progresses Carrington CB. NEJM,
27 Untreated IPF progresses Carrington CB. NEJM, 1978 Better Disease severity Worse Time (years) 27
28 Am J Respir Crit Care Med Vol 176. pp , 2007 How to think about treatment 28
29 Recent trial results have been disappointing Summary of Selected Multi-centered Trials 29
30 Summary of Selected Multi-centered Trials Trial N Primary Endpoint Result Summary of Selected Multi-centered Trials Trial N Primary Endpoint Result Interferon-beta (1999) 167 Progression free survival time Negative 30
31 Summary of Selected Multi-centered Trials Trial N Primary Endpoint Result Imatinib Mesylate 120 Progression free survival Negative Bosentan (BUILD-3) 132 Change in 6MW distance Negative Etanercept 100 Change in DL CO, FVC Negative Interferon-gamma (007) 826 Survival time Negative Interferon-beta (1999) 167 Progression free survival time Negative Summary of Selected Multi-centered Trials Trial N Primary Endpoint Result Pirfenidone (CAPACITY 1) 344 Change in FVC Negative Pirfenidone (CAPACITY 2) 435 Change in FVC Positive Imatinib Mesylate 120 Progression free survival Negative Bosentan (BUILD-3) 132 Change in 6MW distance Negative Etanercept 100 Change in DL CO, FVC Negative Interferon-gamma (007) 826 Survival time Negative Interferon-beta (1999) 167 Progression free survival time Negative 31
32 Summary of Selected Multi-centered Trials Trial N Primary Endpoint Result Ambrisentan (ARTEMIS-IPF) 492 Time to disease progression Potentially Harmful Pirfenidone (CAPACITY 1) 344 Change in FVC Negative Pirfenidone (CAPACITY 2) 435 Change in FVC Positive Imatinib Mesylate 120 Progression free survival Negative Bosentan (BUILD-3) 132 Change in 6MW distance Negative Etanercept 100 Change in DL CO, FVC Negative Interferon-gamma (007) 826 Survival time Negative Interferon-beta (1999) 167 Progression free survival time Negative Summary of Selected Multi-centered Trials Trial N Primary Endpoint Result Coumadin (ACE) 145 Time to disease progression Harmful Ambrisentan (ARTEMIS-IPF) 492 Time to disease progression Potentially Harmful Pirfenidone (CAPACITY 1) 344 Change in FVC Negative Pirfenidone (CAPACITY 2) 435 Change in FVC Positive Imatinib Mesylate 120 Progression free survival Negative Bosentan (BUILD-3) 132 Change in 6MW distance Negative Etanercept 100 Change in DL CO, FVC Negative Interferon-gamma (007) 826 Survival time Negative Interferon-beta (1999) 167 Progression free survival time Negative 32
33 Summary of Selected Multi-centered Trials Trial N Primary Endpoint Result Pred/Aza/N-acetylcysteine (PANTHER) 155 Change in FVC Harmful Coumadin (ACE) 145 Time to disease progression Harmful Ambrisentan (ARTEMIS-IPF) 492 Time to disease progression Potentially Harmful Pirfenidone (CAPACITY 1) 344 Change in FVC Negative Pirfenidone (CAPACITY 2) 435 Change in FVC Positive Imatinib Mesylate 120 Progression free survival Negative Bosentan (BUILD-3) 132 Change in 6MW distance Negative Etanercept 100 Change in DL CO, FVC Negative Interferon-gamma (007) 826 Survival time Negative Interferon-beta (1999) 167 Progression free survival time Negative IPFnet, N Engl J Med 2012;366:
34 IPFnet, N Engl J Med 2012;366:
35 IPFnet, N Engl J Med 2012;366: King et al, New Engl J Med
36 ASCEND Baseline Characteristics King et al, New Engl J Med 2014 Change in FVC over 52 weeks King et al, New Engl J Med
37 Linear slope analysis of FVC change from baseline to week 52 King et al, New Engl J Med 2014 Patients with >10% decline in FVC or death at 52 weeks King et al, New Engl J Med
38 Mean change from baseline in 6-minute walk test distance King et al, New Engl J Med 2014 Patients with decline in FVC, 6mwd or death at 52 weeks King et al, New Engl J Med
39 Categorical change baseline to week 52 in UCSD SOBQ score King et al, New Engl J Med 2014 All-cause mortality in pooled study populations King et al, New Engl J Med
40 Adverse events King et al, New Engl J Med 2014 Adverse events King et al, New Engl J Med
41 Richeldi et al, New Engl J Med 2014 INPULSIS baseline characteristics Richeldi et al, New Engl J Med
42 INPULSIS I primary end point: annual rate of decline in FVC Richeldi et al, New Engl J Med 2014 INPULSIS II primary end point: annual rate of decline in FVC Richeldi et al, New Engl J Med
43 INPULSIS I and II: adjusted annual rate of decline in FVC INPULSIS I Richeldi et al, New Engl J Med 2014 INPULSIS I and II: adjusted annual rate of decline in FVC INPULSIS I INPULSIS II Richeldi et al, New Engl J Med
44 BIBF 1120: Incidence of AE per 12 months Richeldi et al, New Engl J Med 2011 Incidence of investigator-reported AEs within 52 weeks Richeldi et al, New Engl J Med
45 Time to first investigator-reported AE (pooled data) Richeldi et al, New Engl J Med 2014 Time to first adjudicated AE (pooled data) Richeldi et al, New Engl J Med
46 BIBF1120: SGRQ responders ( 4-point decrease) Richeldi et al, New Engl J Med 2011 Change from baseline in SGRQ total score over 52 weeks INPULSIS I Richeldi et al, New Engl J Med
47 Change from baseline in SGRQ total score over 52 weeks INPULSIS I INPULSIS II Richeldi et al, New Engl J Med 2014 Change from baseline in SGRQ over 52 weeks (pooled) Richeldi et al, New Engl J Med
48 Time to death in INPULSIS -1 and INPULSIS -2 (pooled) Richeldi et al, New Engl J Med 2014 Adverse events Richeldi et al, New Engl J Med
49 Adverse events Richeldi et al, New Engl J Med 2014 IPFnet, New Engl J Med
50 PANTHER baseline characteristics IPFnet, New Engl J Med 2014 Changes in FVC and Subgroups before and after the Alert IPFnet, New Engl J Med
51 Changes in FVC and Subgroups before and after the Alert IPFnet, New Engl J Med 2014 Shulgina L, et al. Thorax 2013;68:
52 Co-trimoxazole trial: Kaplan-Meier plots of time until death Intention-to-treat population Per-protocol population Shulgina L, et al. Thorax 2013;68: Which of the following interventions has been shown to have an effect on mortality in patients with IPF? 1. Supplemental oxygen 2. Bosentan 3. Prednisone, Azathioprine, and N-acetyl cysteine 4. Interferon - g 52
53 Which of the following interventions has been shown to have an effect on mortality in patients with IPF? 1. Supplemental oxygen 2. Bosentan 3. Prednisone, Azathioprine, and N-acetyl cysteine 4. Interferon - g 0% 0% 0% 0% Summary Progressive pulmonary fibrosis is a significant clinical problem and occurs in a variety of clinical contexts IPF is a specific and well characterized form of pulmonary fibrosis New treatments are available for IPF 53
Update on Therapies for Idiopathic Pulmonary Fibrosis. Outline
Update on Therapies for Idiopathic Pulmonary Fibrosis Paul Wolters Associate Professor University of California, San Francisco Outline Classification of Interstitial lung disease Clinical classification
More informationNew Horizons The Future of IPF and ILD
New Horizons The Future of IPF and ILD Talmadge E. King, Jr., M.D. Julius R. Krevans Distinguished Professorship in Internal Medicine Chair, Department of Medicine University of California San Francisco
More informationDisclosures. Traditional Paradigm. Overview 4/17/2010. I have relationships with the following organizations and companies:
Disclosures Pharmacological Therapy for ILD What to Use and How to Use It Harold R Collard MD Interstitial Lung Disease Program University of California San Francisco (UCSF) I have relationships with the
More informationProgress in Idiopathic Pulmonary Fibrosis
Progress in Idiopathic Pulmonary Fibrosis David A. Lynch, MB Disclosures Progress in Idiopathic Pulmonary Fibrosis David A Lynch, MB Consultant: t Research support: Perceptive Imaging Boehringer Ingelheim
More informationNew Therapies and Trials in IPF
Conflict of interest disclosure I have the following real or perceived conflicts of interest that relate to this presentation: New Therapies and Trials in IPF Talmadge E. King, Jr., M.D. Julius R. Krevans
More informationINTERSTITIAL LUNG DISEASES: FOCUS ON IDIOPATHIC PULMONARY FIBROSIS (IPF)
INTERSTITIAL LUNG DISEASES: FOCUS ON IDIOPATHIC PULMONARY FIBROSIS (IPF) Marilyn K. Glassberg Csete, M.D. Professor of Medicine, Surgery, and Pediatrics Director, Interstitial and Rare Lung Disease Program
More informationINHALED TREPROSTINIL IN PULMONARY HYPERTENSION DUE TO INTERSTITIAL LUNG DISEASE (PH-ILD)
THE INCREASE STUDY INHALED TREPROSTINIL IN PULMONARY HYPERTENSION DUE TO INTERSTITIAL LUNG DISEASE (PH-ILD) Peter Smith, PharmD Senior Director Product Development, United Therapeutics Corporation 2 SAFE
More informationWim Wuyts. Treatment of idiopathic interstitial pneumonias. March 12 th Interstitial lung diseases state of the art.
nterstitial ungdiseases euven Department of pneumology Unit for interstitial lung diseases University Hospitals Leuven March 12 th 2015 Interstitial lung diseases state of the art Treatment of idiopathic
More informationDIFFERENCES IN FIBROPROLIFERATIVE HEALING IN EXOGENEOUS AND IDIOPATHIC ILDs. ARE THERE ANY?
NIHR Southampton Respiratory Biomedical Research Unit DIFFERENCES IN FIBROPROLIFERATIVE HEALING IN EXOGENEOUS AND IDIOPATHIC ILDs. ARE THERE ANY? Fibrosing Interstitial Lung Diseases CPFS/WASOG/AIPO/ERS
More informationOverview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy
Overview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy Jeff Swigris, DO, MS Director, ILD Program National Jewish Health Disclosures Speaker - Boehringer Ingelheim and Genentech Objectives Describe
More informationChallenges in Pulmonary and Critical Care: 2018
Challenges in Pulmonary and Critical Care: 2018 Interstitial Lung Disease: Evolving Our Understanding of a Deadly Disease 1 Faculty Kevin Flaherty, MD, MS Professor in Pulmonary and Critical Care Medicine
More information4/17/2010 C ini n ca c l a Ev E a v l a ua u t a ion o n of o ILD U dat a e t e i n I LDs
Update in ILDs Diagnosis 101: Clinical Evaluation April 17, 2010 Jay H. Ryu, MD Mayo Clinic, Rochester MN Clinical Evaluation of ILD Outline General aspects of ILDs Classification of ILDs Clinical evaluation
More informationDiffuse Interstitial Lung Diseases: Is There Really Anything New?
: Is There Really Anything New? Sujal R. Desai, MBBS, MD ESTI SPEAKER SUNDAY Society of Thoracic Radiology San Antonio, Texas March 2014 Diffuse Interstitial Lung Disease The State of Play DILDs Is There
More informationNintedanib and Pirfenidone: New Medications in the Management of Idiopathic Pulmonary Fibrosis
Nintedanib and Pirfenidone: New Medications in the Management of Idiopathic Pulmonary Fibrosis Brad Zimmermann, PharmD, MBA Pharmacy Grand Rounds May 02, 2017 Rochester, Minnesota 2017 MFMER slide-1 Objectives
More informationPNEUMOLOGIA 2018 Milano, giugno 2018 INTERSTIZIOPATIE E MALATTIE RARE. Il futuro dell IPF: dove stiamo andando. Carlo Albera
PNEUMOLOGIA 2018 Milano, 14 16 giugno 2018 INTERSTIZIOPATIE E MALATTIE RARE Il futuro dell : dove stiamo andando Carlo Albera Università di Torino, Scuola di Medicina Dipartimento di Scienze Cliniche e
More informationManagement of Idiopathic Pulmonary Fibrosis
Management of Idiopathic Pulmonary Fibrosis Robert Hallowell, M.D. December 22, 2015 Disclosures No financial disclosures What causes IPF? +? VEGF-R Airspace lining TNFa Fibrocytes PDGF Fibroblasts IL-1
More informationConflicts of Interest. Advisory Board: Boehringer-Ingleheim, Genentech/Roche DSMB: Bristol-Myers Squibb, Fibrogen Clinical Endpoint Committee; Merck
Conflicts of Interest Advisory Board: Boehringer-Ingleheim, Genentech/Roche DSMB: Bristol-Myers Squibb, Fibrogen Clinical Endpoint Committee; Merck The Idiopathic Interstitial Pneumonias Idiopathic pulmonary
More informationFinancial disclosure COMMON DIAGNOSES IN HRCT. High Res Chest HRCT. HRCT Pre test. I have no financial relationships to disclose. Anatomy Nomenclature
Financial disclosure I have no financial relationships to disclose. Douglas Johnson D.O. Cardiothoracic Imaging Gaston Radiology COMMON DIAGNOSES IN HRCT High Res Chest Anatomy Nomenclature HRCT Sampling
More informationIdiopathic Pulmonary Fibrosis Treatable and Not Idiopathic
Idiopathic Pulmonary Fibrosis Treatable and Not Idiopathic Brett Ley, MD University of California San Francisco CTS 1/26/18 Disclosures Speaker s bureau honorarium from Genentech (makers of pirfenidone)
More informationDisclosures. Fibrotic lung diseases: Basic Principles, Common Problems, and Reporting. Relevant financial relationships: None. Off-label usage: None
Fibrotic lung diseases: Basic Principles, Common Problems, and Reporting Brandon T. Larsen, MD, PhD Senior Associate Consultant Department of Laboratory Medicine and Pathology Mayo Clinic Arizona Arizona
More informationControversies in Clinical Trials. Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF)
Controversies in Clinical Trials Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF) Controversies to be highlighted by IPF Post-hoc analyses Story Primary end point selection Changing prespecified endpoints
More informationCase Presentations in ILD. Harold R. Collard, MD Department of Medicine University of California San Francisco
Case Presentations in ILD Harold R. Collard, MD Department of Medicine University of California San Francisco Outline Overview of diagnosis in ILD Definition/Classification High-resolution CT scan Multidisciplinary
More informationOFEV MEDIA BACKGROUNDER
OFEV MEDIA BACKGROUNDER 1 What is OFEV (nintedanib*)? 2 How does OFEV (nintedanib*) work? 3 Data overview 4 OFEV (nintedanib*) approval status 1 What is OFEV (nintedanib*)? OFEV (nintedanib*) is a small
More informationExperience with the Compassionate Use Program of nintedanib for the treatment of Idiopathic Pulmonary Fibrosis in Argentina
ORIGINAL 131 RAMR 2017;2:131-135 ISSN 1852-236X Correspondence Gabriela Tabaj gabrielatabaj@gmail.com Received: 11.15.2016 Accepted: 02.03.2017 Experience with the Compassionate Use Program of nintedanib
More informationERS 2016 Congress Highlights Interstitial Lung Disease (ILD)
ERS 216 Congress Highlights Interstitial Lung Disease (ILD) London, UK September 3 rd 7 th 216 The 26 th European Respiratory Society International Congress, (ERS) the largest respiratory meeting in the
More informationA case of a patient with IPF treated with nintedanib. Prof. Kreuter and Prof. Heussel
A case of a patient with IPF treated with nintedanib Prof. Kreuter and Prof. Heussel Case Overview This case describes the history of a patient with IPF who, at the time of diagnosis, had symptoms typical
More informationNINTEDANIB MEDIA BACKGROUNDER
NINTEDANIB MEDIA BACKGROUNDER 1. What is nintedanib? 2. How does nintedanib work? 3. Data overview 4. International treatment guidelines for IPF 1. What is nintedanib? Nintedanib (OFEV a ) is a small molecule
More information5/9/2015. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. No, I am not a pulmonologist! Radiology
Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective No, I am not a pulmonologist! Radiology Pathology Clinical 1 Everyone needs a CT Confidence in diagnosis Definitive HRCT +
More informationRandomized Trial of Acetylcysteine in Idiopathic Pulmonary Fibrosis
original article Randomized Trial of in Idiopathic Pulmonary Fibrosis The Idiopathic Pulmonary Fibrosis Clinical Research Network* ABSTRACT Background has been suggested as a beneficial treatment for idiopathic
More information11/10/2014. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. Radiology
Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective Radiology Pathology Clinical 1 Role of HRCT Diagnosis Fibrosis vs. inflammation Next step in management Response to treatment
More informationDiagnostic challenges in IPF
Medicine, Nursing and Health Sciences Diagnostic challenges in IPF Dr Ian Glaspole Central and Eastern Clinical School, Alfred Hospital and Monash University March 2015 Disclosures Consultancy fees from
More informationStrategies for Updated Treatment Options for IPF
Strategies for Updated Treatment Options for IPF Paul W. Noble, MD Vera and Paul Guerin Family Distinguished Chair in Pulmonary Medicine Professor and Chair Department of Medicine Director, Women's Guild
More informationTherapies for Idiopathic Pulmonary Fibrosis Pharmacologic, Non-Pharmacologic
Therapies for Idiopathic Pulmonary Fibrosis Pharmacologic, Non-Pharmacologic Amy Olson, MD, MSPH Associate Professor, Division of Pulmonary and Critical Care Medicine National Jewish Health, Denver, CO
More informationDIAGNOSTIC NOTE TEMPLATE
DIAGNOSTIC NOTE TEMPLATE SOAP NOTE TEMPLATE WHEN CONSIDERING A DIAGNOSIS OF IDIOPATHIC PULMONARY FIBROSIS (IPF) CHIEF COMPLAINT HISTORY OF PRESENT ILLNESS Consider IPF as possible diagnosis if any of the
More informationDiagnosing ILD. What is important in 2016? Chris Grainge
Diagnosing ILD What is important in 2016? Chris Grainge Senior Staff Specialist Respiratory Medicine John Hunter Hospital Conjoint A/Prof University of Newcastle Conflict of interest I have acted as a
More informationGuidelines for Diagnosis and Treatment of IPF
Guidelines for Diagnosis and Treatment of IPF Katerina Antoniou, MD, PhD Lecturer in Thoracic Medicine ERS ILD Group Secretary Medical School, University of Crete Classification of Interstitial Lung Disease
More informationINTERSTITIAL LUNG DISEASE. Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018
INTERSTITIAL LUNG DISEASE Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018 Interstitial Lung Disease Interstitial Lung Disease Prevalence by Diagnosis: Idiopathic Interstitial
More informationDiagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines
Diagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines Rebecca Keith, MD Assistant Professor, Division of Pulmonary and Critical Care Medicine National Jewish Health, Denver, CO Objectives
More informationNon-neoplastic Lung Disease II
Pathobasic Non-neoplastic Lung Disease II Spasenija Savic Prince Pathology Program Systematic approach to surgical lung biopsies with ILD Examples (chronic ILD): Idiopathic interstitial pneumonias: UIP,
More informationPresente e futuro della terapia della fibrosi polmonare idiopatica
Presente e futuro della terapia della fibrosi polmonare idiopatica Antonella Caminati U.O. di Pneumologia e Terapia Semi Intensiva Servizio di Fisiopatologia Respiratoria ed Emodinamica Polmonare Osp.
More informationInterstitial Lung Disease (ILD)
Interstitial Lung Disease (ILD) ILD comprises more than 130 distinct disorders Characterized by cellular proliferation, cellular infiltration, and/or fibrosis of the lung parenchyma not due to infection
More informationA Review of Interstitial Lung Diseases. Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco
A Review of Interstitial Lung Diseases Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco Outline Overview of diagnosis in ILD Why it is important Definition/Classification
More informationCurrent diagnostic recommendations for ILD: The multidisciplinary meeting TSANZSRS ASM
Medicine, Nursing and Health Sciences Current diagnostic recommendations for ILD: The multidisciplinary meeting Dr Ian Glaspole Central and Eastern Clinical School, Alfred Hospital and Monash University
More informationNAVIGATING the NEW ERA in IPF: Idiopathic Pulmonary Fibrosis
NAVIGATING the NEW ERA in IPF: Idiopathic Pulmonary Fibrosis Mark J Rumbak, MD Division Director Pulmonary, Critical Care and Sleep Medicine Morsani College of Medicine University of South Florida, Tampa
More informationManagement of Co morbidities in Idiopathic Pulmonary Fibrosis. Disclosures
Management of Co morbidities in Idiopathic Pulmonary Fibrosis Joyce S. Lee, MD MAS Director, Interstitial Lung Disease Clinic University of California, San Francisco Disclosures Intermune, advisory board
More information9/12/18. Emerging Challenges in Primary Care: Navigating the Maze of Interstitial Lung Disease: Improving Outcomes through Early Diagnosis
Emerging Challenges in Primary Care: 2018 Navigating the Maze of Interstitial Lung Disease: Improving Outcomes through Early Diagnosis Faculty Kevin Flaherty, MD, MS Professor in Pulmonary and Critical
More informationNONE OVERVIEW FINANCIAL DISCLOSURES UPDATE ON IDIOPATHIC PULMONARY FIBROSIS/IPF (UIP) FOR PATHOLOGISTS. IPF = Idiopathic UIP Radiologic UIP Path UIP
UPDATE ON IDIOPATHIC PULMONARY FIBROSIS/IPF () FOR PATHOLOGISTS Thomas V. Colby, M.D. Professor of Pathology (Emeritus) Mayo Clinic Arizona FINANCIAL DISCLOSURES NONE OVERVIEW IPF Radiologic Dx Pathologic
More informationInternational consensus statement on idiopathic pulmonary fibrosis
Eur Respir J 2001; 17: 163 167 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2001 European Respiratory Journal ISSN 0903-1936 PERSPECTIVE International consensus statement on idiopathic
More informationEpidemiology and classification of smoking related interstitial lung diseases
Epidemiology and classification of smoking related interstitial lung diseases Šterclová M. Department of Respiratory Diseases, Thomayer Hospital, Prague, Czech Republic Supported by an IGA Grant No G 1207
More informationRole of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study
36 Journal of The Association of Physicians of India Vol. 64 May 2016 Original Article Role of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study KP Suraj 1, Neethu K Kumar 2, E
More informationOutline Definition of Terms: Lexicon. Traction Bronchiectasis
HRCT OF IDIOPATHIC INTERSTITIAL PNEUMONIAS Disclosures Genentech, Inc. Speakers Bureau Tadashi Allen, MD University of Minnesota Assistant Professor Diagnostic Radiology 10/29/2016 Outline Definition of
More informationCTD-related Lung Disease
13 th Cambridge Chest Meeting King s College, Cambridge April 2015 Imaging of CTD-related Lung Disease Dr Sujal R Desai King s College Hospital, London Disclosure Statement No Disclosures / Conflicts of
More informationDifferential diagnosis
Differential diagnosis Idiopathic pulmonary fibrosis (IPF) is part of a large family of idiopathic interstitial pneumonias (IIP), one of four subgroups of interstitial lung disease (ILD). Differential
More informationA Review of Interstitial Lung Diseases
Outline A Review of Interstitial Lung Diseases Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco Overview of diagnosis in ILD Why it is important Definition/Classification
More informationTriple kinase inhibitor with phosphodiesterase-5 inhibitor for idiopathic pulmonary fibrosis
Editorial Triple kinase inhibitor with phosphodiesterase-5 inhibitor for idiopathic pulmonary fibrosis Tomoo Kishaba Department of Respiratory Medicine, Okinawa Chubu Hospital, Uruma City, Okinawa, Japan
More informationPulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment
Prague, June 2014 Pulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment Katerina M. Antoniou, MD, PhD As. Professor in Thoracic Medicine ERS ILD Group Secretary Medical School,
More informationTimely Topics in Pulmonary Medicine
Disclosures Timely Topics in Pulmonary Medicine I have nothing to disclose! Lorriana Leard, MD Associate Professor of Clinical Medicine Chief of Clinical Operations UCSF Pulmonary, Critical Care, Allergy
More informationIPF : Dalla Diagnosi alla Terapia
IV Forum di Pneumologia Interventistica Bologna 5-6 Giugno 2015 IPF : Dalla Diagnosi alla Terapia Sergio Harari U.O. di Pneumologia e UTIR Servizio di Emodinamica e Fisiopatologia Respiratoria Ospedale
More informationCase 1 : Question. 1.1 What is the intralobular distribution? 1. Centrilobular 2. Perilymphatic 3. Random
Interesting case Case 1 Case 1 : Question 1.1 What is the intralobular distribution? 1. Centrilobular 2. Perilymphatic 3. Random Case 1: Answer 1.1 What is the intralobular distribution? 1. Centrilobular
More informationConnective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates
Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates Maria Elena Vega, M.D Assistant Professor of Medicine Lewis Katz School of Medicine at Temple University Nothing to
More informationManish Powari Regional Training Day 10/12/2014
Manish Powari Regional Training Day 10/12/2014 Large number of different types of Interstitial Lung Disease (ILD). Most are very rare Most patients present with one of a smaller number of commoner diseases
More informationRegulatory Status FDA-approved indication: Ofev is a kinase inhibitor indicated for the treatment of idiopathic pulmonary fibrosis (IPF) (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.45.05 Subject: Ofev Page: 1 of 5 Last Review Date: March 17, 2017 Ofev Description Ofev (nintedanib)
More informationPatient with FVC>90% predicted. Demosthenes Bouros, Vasilios Tzilas University of Athens
Patient with FVC>90% predicted Demosthenes Bouros, Vasilios Tzilas University of Athens CASE OVERVIEW A 63-year-old, male patient with progressive exertional dyspnoea lasting for 2 years and dry cough
More informationDiffuse interstitial lung diseases (DILDs) are a heterogeneous group of non-neoplastic, noninfectious
Focused Issue of This Month Diagnostic Approaches to Diffuse Interstitial Lung Diseases Dong Soon Kim, MD Department of Pulmonary and Critical Care Medicine, University of Ulsan College of Medicine E -
More informationSummary of eligibility criteria for the Phase 3 multinational studies
SUPPLEMENTAL MATERIAL Table 1 Summary of eligibility criteria for the Phase 3 multinational studies CAPACITY (Studies 004 and 006) ASCEND (Study 016) Age 40 to 80 years Confident IPF diagnosis within the
More informationOctober 30, The Westin Princeton at Forrestal Village 201 Village Boulevard Princeton, NJ Marilyn Glassberg Csete, MD FACP, FCCP
October 3, 215 The Westin Princeton at Forrestal Village 21 Village Boulevard Princeton, NJ 854 Marilyn Glassberg Csete, MD FACP, FCCP Professor of Medicine, Surgery, and Pediatrics at the University of
More informationKD : A Phase 2 Trial of KD025 to Assess Safety, Efficacy and Tolerability in Patients with Idiopathic Pulmonary Fibrosis (IPF)
-207: A Phase 2 Trial of to Assess Safety, Efficacy and Tolerability in Patients with Idiopathic Pulmonary Fibrosis (IPF) K. F. Gibson 1, F. Averill 2, T.E. Albertson 3, D. M. Baratz 4, S. Chaudhary 5,
More informationIdiopathic pulmonary fibrosis (IPF) is a progressive. Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes
Eur Respir Rev 2012; 21: 124, 161 167 DOI: 10.1183/09059180.00001112 CopyrightßERS 2012 REVIEW: IPF Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes Vincent
More informationIPF: Epidemiologia e stato dell arte
IPF: Epidemiologia e stato dell arte Clinical Classification Diffuse parenchimal lung diseases Exposure-related: - occupational - environmental - medication Desquamative interstitial pneumonia Idiopathic
More informationEvaluating New Treatment Options
Evaluating New Treatment Options Steven D. Nathan, MD Clinical Practice Guideline Changes 211 ATS/ERS/JRS/ALAT Recommendations Treatment of IPF combines nonpharmacologic and pharmacologic strategies, and
More informationCOI: no conflicts of interest to declare
Idiopathic versus secondary Usual Interstitial Pneumonia (UIP) pattern in a series of 96 consecutive surgical lung biopsies: The value of histologic ancillary findings in a multidisciplinary discussion
More informationPrednisone, Azathioprine, and N-Acetylcysteine for Pulmonary Fibrosis
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article,, and N-Acetylcysteine for Pulmonary Fibrosis The Idiopathic Pulmonary Fibrosis Clinical Research Network* A bs tr ac t The members
More informationUnpaid scientific collaborator & advisor with Veracyte, Inc.
Diagnosis and Classification of Idiopathic Interstitial Pneumonias: Role of Histopathology in the Golden Age of Consensus Jeffrey L. Myers, M.D. A. James French Professor of Diagnostic Pathology Vice Chair
More informationDefinition, classification and epidemiology
Interstitial Lung Diseases Definition, classification and epidemiology Haluk Türktaş Professor of Pulmonary Medicine Gazi University Ankara Interstitial Lung Diseases Definition of ILD A diverse group
More informationFaculty. Luca Richeldi, MD, PhD (Chair) Professor of Respiratory Medicine Chair of Interstitial Lung Disease University of Southampton Southampton, UK
Faculty Luca Richeldi, MD, PhD (Chair) Professor of Respiratory Medicine Chair of Interstitial Lung Disease University of Southampton Southampton, UK Kevin K. Brown, MD Professor of Medicine, Vice Chair,
More informationPathologic Assessment of Interstitial Lung Disease
Pathologic Assessment of Interstitial Lung Disease Dry and itchy? It could be eczema or fungal infection. We don t need to worry, the drugs aren t that dangerous. Kirk D. Jones, MD UCSF Dept. of Pathology
More informationLines and crackles. Making sense of ILD
Lines and crackles Making sense of ILD Case JM 65 year old male Gradual shortness of breath, going on over a year Some dry cough Ex-smoker, quit 10 years ago Crackles in the bases CXR presented Sent to
More informationOfficial ATS/ERS/JRS/ALAT Clinical Practice Guidelines: Treatment of Idiopathic Pulmonary Fibrosis
Official ATS/ERS/JRS/ALAT Clinical Practice Guidelines: Treatment of Idiopathic Pulmonary Fibrosis An Update of the 2011 Clinical Practice Guideline Online Supplement Ganesh Raghu, Bram Rochwerg, Yuan
More informationPrognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis
Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis JULIE A. BJORAKER, JAY H. RYU, MARK K. EDWIN, JEFFREY L. MYERS, HENRY D. TAZELAAR, DARRELL R. SCHROEDER, and KENNETH
More informationIdiopathic Pulmonary Fibrosis: The Importance of Qualitative and Quantitative Phenotyping
Idiopathic Pulmonary Fibrosis: The Importance of Qualitative and Quantitative Phenotyping K. R. Flaherty Division of Pulmonary and Critical Care Medicine, University of Michigan Health System, Ann Arbor,
More informationPFF HEALTH CARE PROFESSIONAL WEBINAR SERIES. Welcome!
PFF HEALTH CARE PROFESSIONAL WEBINAR SERIES Welcome! AGENDA TOPICS Welcome & Introduction Dr. Gregory Cosgrove, MD Chief Medical Officer Pulmonary Fibrosis Foundation PFF Resources Dolly Kervitsky, RCP,
More informationIPF - Inquadramento clinico
IPF - Inquadramento clinico Sergio Harari Unità Operativa di Pneumologia UTIR Servizio di Fisiopat. Resp. e Emodinamica Polmonare Ospedale S. Giuseppe, Milano Clinical Classification Diffuse parenchimal
More informationIdiopathic Pulmonary Fibrosis: A Study of 46 Patients from Western India: Clinical Presentations and Survival
Turk Thorac J 205; 6:4-20 DOI: 0.552/ttd.205.4584 ORIGINAL INVESTIGATION Idiopathic Pulmonary Fibrosis: A Study of 46 Patients from Western India: Clinical Presentations and Survival Subramanian Natarajan,
More informationGLPG1690 FLORA topline results
GLPG1690 FLORA topline results Webcast presentation 10 August 2017 Disclaimer This presentation contains forward-looking statements, including (without limitation) statements concerning the potential activity
More informationLiebow and Carrington's original classification of IIP
Liebow and Carrington's original classification of IIP-- 1969 Eric J. Stern MD University of Washington UIP Usual interstitial pneumonia DIP Desquamative interstitial pneumonia BIP Bronchiolitis obliterans
More informationChallenges in the Diagnosis of Interstitial Lung Disease
Challenges in the Diagnosis of Interstitial Lung Disease Kirk D. Jones, MD UCSF Dept. of Pathology kirk.jones@ucsf.edu Overview New Classification of IIP Prior classification Modifications for new classification
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Idiopathic Pulmonary Fibrosis Therapy Table of Contents Coverage Policy... 1 General Background... 4 Coding/Billing Information... 7 References... 7 Effective
More informationTBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than
TBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than PAP) BAL is not required as a diagnostic tool in patients
More informationChallenges in the classification of fibrotic ILD
Review SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES 2015; 32; Suppl. 1: 4-9 Mattioli 1885 Challenges in the classification of fibrotic ILD Elisabeth Bendstrup 1, Toby M. Maher 2, Effrosyni D. Manali
More informationBronchoalveolar Lavage and Histopathologic Diagnosis Based on Biopsy
Idiopathic Pulmonary Fibrosis Bronchoalveolar Lavage and Histopathologic Diagnosis Based on Biopsy JMAJ 46(11): 469 474, 2003 Yukihiko SUGIYAMA Professor, Division of Pulmonary Medicine, Department of
More informationHypersensitivity Pneumonitis Common Diagnostic and Treatment Dilemmas
Hypersensitivity Pneumonitis Common Diagnostic and Treatment Dilemmas Rishi Raj MD Director, Interstitial Lung Diseases Program Clinical Professor of Pulmonary and Critical Care Medicine Stanford University
More informationUntil approximately 40 yrs ago, clinical. Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis REVIEW: IPF
Eur Respir Rev 2012; 21: 124, 147 151 DOI: 10.1183/09059180.00000912 CopyrightßERS 2012 REVIEW: IPF Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis Luca Richeldi ABSTRACT:
More informationIdiopathic pulmonary fibrosis
Pharmacologic Treatments for Idiopathic Pulmonary Fibrosis This chronic disease has historically lacked an effective treatment option, but the FDA recently approved two: pirfenidone and nintedanib. This
More informationPerspectives ILD Diagnosis and Treatment in 5-10 years
Perspectives ILD Diagnosis and Treatment in 5-10 years Brett Ley, MD Department of Medicine The (Near) Future of ILD Diagnosis and Treatment 1. Combination therapy for Idiopathic Pulmonary Fibrosis 2.
More informationCurrent Management of IPF and. Dr R Lakshmi Narasimhan Dept of Pulmonary Medicine
Current Management of IPF and fibrosing ILDs Dr R Lakshmi Narasimhan Dept of Pulmonary Medicine Introduction Idiopathic pulmonary fibrosis clinical course is variable and long term survival is poor Therapy
More informationNew approaches to the design of clinical trials in idiopathic pulmonary fibrosis
New approaches to the design of clinical trials in idiopathic pulmonary fibrosis Clin. Invest. (2013) 3(6), 531 544 Idiopathic pulmonary fibrosis (IPF) is one of the major challenges for respiratory medicine,
More informationMissing data in IPF trials: do not let methodological issues undermine a major therapeutic breakthrough
EDITORIAL INTERSTITIAL LUNG DISEASE Missing data in IPF trials: do not let methodological issues undermine a major therapeutic breakthrough Gabriel Thabut 1,2, Bruno Crestani 2,3, Raphaël Porcher 4,5 and
More informationInterstitial Lung Disease
Interstitial Lung Disease Interstitial lung disease (ILD) is a broad category of lung diseases that includes more than 130 disorders which are characterized by scarring (i.e. fibrosis ) and/or inflammation
More informationDisclosures. Clinical Approach: Evaluating CTD-ILD for the pulmonologist. ILD in CTD. connective tissue disease or collagen vascular disease
Disclosures Clinical Approach: Evaluating CTD-ILD for the pulmonologist Industry relationships: Actelion, atyr Pharma, Boehringer-Ingelheim, Genentech- Roche, Gilead Aryeh Fischer, MD Associate Professor
More information